MedPath

Galderma Group AG

🇨🇭Switzerland
Ownership
-
Employees
-
Market Cap
$22.9B
Website
http://www.galderma.com/

Study to Evaluate Satisfaction After Treatment With Restylane

Not Applicable
Completed
Conditions
Cheek Augmentation
Interventions
Device: Restylane Volyme
Device: Restylane Lyft Lidocaine
First Posted Date
2020-11-20
Last Posted Date
2024-03-06
Lead Sponsor
Galderma R&D
Target Recruit Count
60
Registration Number
NCT04638816
Locations
🇨🇦

Galderma Study Site, Montreal, Quebec, Canada

New Dermal Filler for Chin Correction and Augmentation

Not Applicable
Completed
Conditions
Chin Augmentation and Correction
Interventions
Device: Hyaluronic Acid
First Posted Date
2020-11-17
Last Posted Date
2022-08-25
Lead Sponsor
Galderma R&D
Target Recruit Count
140
Registration Number
NCT04631263
Locations
🇨🇦

Galderma Research Site, Westmount, Quebec, Canada

Open Label Extension for 43USSA1812

Not Applicable
Completed
Conditions
Cheek
Wrinkle
Interventions
Device: Sculptra Aethestic reconsituted with 8ml Sterile Water for Injection
First Posted Date
2020-10-20
Last Posted Date
2025-06-26
Lead Sponsor
Galderma R&D
Target Recruit Count
111
Registration Number
NCT04595331
Locations
🇺🇸

Galderma Research Site, Spring, Texas, United States

🇺🇸

Galderma Research site, San Diego, California, United States

A Study to Assess the Effects of Nemolizumab on Cytochrome P450 Substrates in Participants With Moderate-to-Severe Atopic Dermatitis

Phase 2
Completed
Conditions
Atopic Dermatitis
Interventions
Drug: CYP 450 Substrates
First Posted Date
2020-09-24
Last Posted Date
2024-12-05
Lead Sponsor
Galderma R&D
Target Recruit Count
17
Registration Number
NCT04562116
Locations
🇺🇸

8894 Galderma Investigational Site, North Hollywood, California, United States

🇺🇸

9954 Galderma Investigational Site, Hallandale Beach, Florida, United States

🇺🇸

9923 Galderma Investigational Site, Miami, Florida, United States

and more 3 locations

Restylane Defyne in a Stepwise Treatment Approach

Not Applicable
Completed
Conditions
Lower Face Folds and Lines
Interventions
Device: Restylane Defyne
First Posted Date
2020-08-20
Last Posted Date
2023-04-14
Lead Sponsor
Galderma R&D
Target Recruit Count
62
Registration Number
NCT04520997
Locations
🇮🇹

Galderma Research Site, Palermo, Italy

A Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN)

Phase 3
Completed
Conditions
Prurigo Nodularis
Interventions
Drug: Placebo
First Posted Date
2020-08-06
Last Posted Date
2024-07-10
Lead Sponsor
Galderma R&D
Target Recruit Count
274
Registration Number
NCT04501679
Locations
🇨🇭

Galderma Investigational Site, Weinfelden, Switzerland

Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN)

Phase 3
Completed
Conditions
Prurigo Nodularis
Interventions
First Posted Date
2020-08-06
Last Posted Date
2024-07-10
Lead Sponsor
Galderma R&D
Target Recruit Count
286
Registration Number
NCT04501666
Locations
🇬🇧

Galderma Investigational Site, Newcastle Upon Tyne, United Kingdom

A Study to Compare Efficacy and Safety of Trifarotene Cream When Used With an Oral Antibiotic for the Treatment of Severe Acne Vulgaris (AV)

First Posted Date
2020-06-30
Last Posted Date
2022-05-10
Lead Sponsor
Galderma R&D
Target Recruit Count
202
Registration Number
NCT04451330
Locations
🇵🇷

Galderma Investigational Site, Aibonito, Puerto Rico

A Study to Assess Immunization Responses in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis Treated With Nemolizumab

Phase 2
Completed
Conditions
Dermatitis, Atopic
Interventions
Drug: Placebo
First Posted Date
2020-04-28
Last Posted Date
2025-06-05
Lead Sponsor
Galderma R&D
Target Recruit Count
242
Registration Number
NCT04365387
Locations
🇺🇸

Galderma Investigational Site (Site#8213), Ormond Beach, Florida, United States

🇺🇸

Galderma Investigational Site (Site#8428), Philadelphia, Pennsylvania, United States

🇺🇸

Galderma Investigational Site (Site#9922), Phoenix, Arizona, United States

and more 60 locations

A Study to Assess Recurrence of Actinic Keratosis in Participants Treated With Methyl Aminolevulinate Hydrochloride Cream or Vehicle Cream Who Achieved Complete Response to Treated Lesions in Earlier Study

Phase 3
Terminated
Conditions
Keratosis, Actinic
Interventions
Drug: MAL Cream
Drug: Vehicle cream
First Posted Date
2020-02-13
Last Posted Date
2023-10-10
Lead Sponsor
Galderma R&D
Target Recruit Count
125
Registration Number
NCT04269395
Locations
🇺🇸

Galderma Investigational Site (Site#8447), Fort Smith, Arkansas, United States

🇺🇸

Galderma Investigational Site (Site#8577), Encinitas, California, United States

🇺🇸

Galderma Investigational Site (Site#8636), Fountain Valley, California, United States

and more 40 locations
© Copyright 2025. All Rights Reserved by MedPath